Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phentolamine - Ocuphire Pharma

Drug Profile

Phentolamine - Ocuphire Pharma

Alternative Names: 0.75% phentolamine ophthalmic solution - Ocularis Pharma; 1% phentolamine mesylate - Ocularis Pharma; Nyxol; Phentolamine mesylate ophthalmic solution - Ocularis Pharma; RYZUMVI

Latest Information Update: 18 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ocularis Pharma
  • Developer Ocuphire Pharma
  • Class Antiglaucomas; Erectile dysfunction therapies; Eye disorder therapies; Imidazoles; Peripheral vasodilators; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Alpha 2 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Registered Mydriasis
  • Phase III Nyctalopia; Presbyopia
  • Phase II Ocular hypertension; Open-angle glaucoma

Most Recent Events

  • 08 Mar 2024 Ocuphire plans the phase III LYNX-2 study in Nyctalopia (Dim light vision disturbances) in USA in the first half of 2024
  • 08 Mar 2024 Ocuphire Pharma plans to launch phentolamine for Mydriasis in USA in the H1 2024
  • 04 Jan 2024 Ocuphire Pharma anticipates to submit regulatory applications in Nyctalopia
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top